Exelixis - Stock Price History | EXEL

Historical daily share price chart and data for Exelixis since 2021 adjusted for splits. The latest closing stock price for Exelixis as of September 27, 2021 is 20.70.
  • The all-time high Exelixis stock closing price was 49.25 on July 26, 2000.
  • The Exelixis 52-week high stock price is 25.77, which is 24.5% above the current share price.
  • The Exelixis 52-week low stock price is 16.19, which is 21.8% below the current share price.
  • The average Exelixis stock price for the last 52 weeks is 21.35.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Exelixis Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 21.4541 17.6600 27.4200 14.4600 20.0700 13.90%
2019 20.2044 19.9300 24.7600 15.1500 17.6200 -10.42%
2018 21.3594 31.4000 31.8900 13.6500 19.6700 -35.30%
2017 23.6912 14.7300 30.9300 14.7300 30.4000 103.89%
2016 8.8409 5.4900 18.2500 3.6400 14.9100 164.36%
2015 4.1775 1.6500 6.6200 1.5800 5.6400 291.67%
2014 3.7219 6.1800 8.2400 1.2900 1.4400 -76.51%
2013 5.0341 4.8300 6.1300 4.4000 6.1300 34.14%
2012 5.0902 4.6600 6.4700 4.2840 4.5700 -3.48%
2011 8.2141 8.4950 12.4500 3.9500 4.7350 -42.33%
2010 5.2375 7.5000 9.0800 2.8800 8.2100 11.40%
2009 5.5646 5.2200 8.0000 4.1600 7.3700 46.81%
2008 5.8875 8.7400 8.7400 2.4000 5.0200 -41.83%
2007 10.4600 9.4700 12.3800 7.9700 8.6300 -4.11%
2006 9.8708 9.7400 12.1200 7.5700 9.0000 -4.46%
2005 7.7525 9.2000 9.8600 6.1100 9.4200 -0.84%
2004 8.5272 7.0000 10.2200 6.1200 9.5000 34.75%
2003 7.2335 7.6090 9.3800 5.1700 7.0500 -11.88%
2002 8.0600 15.8100 16.5000 3.0200 8.0000 -51.87%
2001 13.7222 12.6900 19.1500 8.0000 16.6200 13.60%
2000 28.8885 14.7500 49.2500 11.5600 14.6300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.522B $0.988B
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29